Nautilus Biotech S.A.
Nautilus Biotech S.A., headquartered in France, is a pioneering company in the biotechnology sector, specialising in the development of innovative protein-based therapeutics. Founded in 2015, Nautilus has rapidly established itself as a leader in the biopharmaceutical industry, focusing on advanced drug discovery and development processes that leverage cutting-edge technologies. With a strong presence in Europe and expanding operations globally, Nautilus Biotech is renowned for its unique approach to protein engineering, which enhances the efficacy and safety of therapeutic proteins. The company’s core offerings include bespoke protein design and optimisation services, setting it apart in a competitive market. Nautilus has achieved significant milestones, including strategic partnerships and successful product launches, solidifying its position as a key player in the biotechnology landscape.
DitchCarbon Score
How does Nautilus Biotech S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Nautilus Biotech S.A.'s score of 21 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Nautilus Biotech S.A.'s reported carbon emissions
Nautilus Biotech S.A., headquartered in France, currently does not have publicly available carbon emissions data for recent years. As such, specific figures regarding their Scope 1, 2, or 3 emissions are not provided. Additionally, there are no documented reduction targets or climate pledges outlined by the company at this time. In the absence of specific emissions data, it is important to note that many companies in the biotechnology sector are increasingly focusing on sustainability and climate commitments. This often includes setting science-based targets for emissions reductions and engaging in initiatives aimed at minimising their carbon footprint. Nautilus Biotech S.A. may be participating in similar industry trends, although specific details are not available. For stakeholders and environmentally conscious investors, it is advisable to monitor Nautilus Biotech S.A.'s future disclosures regarding their carbon emissions and climate strategies as they evolve.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Nautilus Biotech S.A. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
